ky1005

Small moleculeexperimental

Clinical trial activity

20 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
15
Phase 3
4
Phase 4
0

Earliest trial started May 1, 2017 (NCT03161288)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ky1005

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07146750Phase 1Aug 25, 2025Sanofi
NCT06686628Phase 1Nov 13, 2024Sanofi
NCT06557772Phase 2Aug 29, 2024Sanofi
NCT06444451Phase 2Jun 6, 2024Sanofi
NCT06407934Phase 3May 8, 2024Sanofi
NCT06195072Phase 2Apr 15, 2024Boehringer Ingelheim, Sanofi, Scleroderma Research Foundation, Inc.
NCT06224348Phase 3Jan 18, 2024Sanofi
NCT06181435Phase 3Dec 27, 2023Sanofi
NCT06130566Phase 3Nov 8, 2023Sanofi
NCT06118099Phase 2Nov 1, 2023Sanofi
NCT06015308Phase 2Oct 6, 2023Sanofi
NCT06033833Phase 2Sep 5, 2023Sanofi
NCT05769777Phase 2Apr 3, 2023Sanofi
NCT05492578Phase 2Aug 22, 2022Sanofi
NCT05421598Phase 2Jun 30, 2022Sanofi
NCT05796479Phase 1Apr 28, 2022Sanofi
NCT05131477Phase 2Dec 7, 2021Kymab Limited, Sanofi
NCT04449939Phase 1Jul 7, 2020Hammersmith Medicines Research, Kymab Limited
NCT03754309Phase 2Dec 13, 2018Kymab Limited, Universitaetsklinikum Schleswig-Holstein
NCT03161288Phase 1May 1, 2017Kymab Limited
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SanofiFor profit171532021
Kymab LimitedFor profit4422017
Boehringer IngelheimFor profit1012024
Hammersmith Medicines ResearchFor profit1012020
Scleroderma Research Foundation, Inc.Academic/Hospital1112024
Universitaetsklinikum Schleswig-HolsteinAcademic/Hospital1012018
6 organizations
Page 1 / 1